PIKFYVE and neoplasm: MC38-OVA tumor had a higher proportion of MC38 tumor neoantigen-specific (KSPWFTTL) tetramer+ CD8+ T cells (Fig. 4m, n) demonstrating that Pikfyve loss enhanced DC-mediated antigen presentation and priming of antigen-specific CD8+ T cells in an in vivo tumor model.